Arimasu O, Hashira S, Fujii R
Jpn J Antibiot. 1986 Aug;39(8):2077-83.
Ceftazidime (CAZ) was evaluated for its safety and efficacy in 27 newborns. Four confirmed cases of bacterial infections were cured by the CAZ therapy (efficacy rate 100%). The CAZ was assessed as effective in sepsis (2) and urinary tract infections (2). Main pathogens which responded to CAZ were Escherichia coli, Enterobacter cloacae and Acinetobacter anitratum. As adverse effects, elevations of GOT and GPT (1 case) were found to be associated with the CAZ therapy. Half-lives of the serum levels in mature infants were 1.93-3.52 hours, and those in low birth weight infants were 2.92-4.17 hours. Penetration into the cerebrospinal fluid in 1 case of viral meningitis was satisfactory. The data suggest that CAZ is a safe and effective injectable antibiotic when used in newborn with infection caused by CAZ-susceptible bacteria.
对27例新生儿使用头孢他啶（CAZ）进行安全性和有效性评估。4例确诊细菌感染病例经CAZ治疗治愈（有效率100%）。CAZ在败血症（2例）和尿路感染（2例）中被评估为有效。对CAZ有反应的主要病原体为大肠杆菌、阴沟肠杆菌和抗硝不动杆菌。作为不良反应，发现1例谷草转氨酶（GOT）和谷丙转氨酶（GPT）升高与CAZ治疗有关。成熟婴儿血清水平的半衰期为1.93 - 3.52小时，低出生体重婴儿的半衰期为2.92 - 4.17小时。1例病毒性脑膜炎患者脑脊液中的药物渗透情况良好。数据表明，当用于治疗由对CAZ敏感细菌引起感染的新生儿时，CAZ是一种安全有效的注射用抗生素。
